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Introduction
Millions of Muslims fast from dawn until dusk dur-
ing the annual Islamic holy month of Ramadan.
During the fast, Muslims are required to abstain not
only from food and drink, but also from receiving
oral medications. The Koran does exempt sick people
from fasting. As the act of fasting increases the risk
of hypoglycaemia in patients with diabetes, in part
related to potentially impaired counter-regulatory
responses to low blood glucose (1), treatment guide-
lines recommend that most patients with diabetes
should not fast during Ramadan (2,3). However, in
an epidemiologic study, the majority (78.8%) of
patients with type 2 diabetes fasted for at least
15 days during Ramadan, with a 7.5-fold increase in
the incidence of severe hypoglycaemia observed rela-
tive to the preceding months (4). The incidence of
hypoglycaemic events was overall low, but was prob-
ably underestimated in this study, because only
events requiring hospitalisation were counted. As
many diabetic patients will fast during Ramadan
despite the potential fasting-related risks and compli-
SUMMARY
Aims: To compare the incidence of symptomatic hypoglycaemia in fasting Muslim
patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during
Ramadan. Methods: Patients with type 2 diabetes (age ‡ 18 years) who were
treated with a stable dose of a sulphonylurea with or without metformin for at
least 3 months prior to screening, who had an HbA1c < 10% and who expressed
their intention to daytime fast during Ramadan were eligible for this open-label
study. Patients were randomised in a 1 : 1 ratio to either switch to sitagliptin
100 mg qd or to remain on their prestudy sulphonylurea. Patients completed daily
diary cards to document information on hypoglycaemic symptoms and complica-
tions. The primary end-point was the overall incidence of symptomatic hypoglyca-
emia recorded during Ramadan. Results: Of the 1066 patients randomised, 1021
(n = 507 for sitagliptin and n = 514 for sulphonylurea) returned at least one com-
pleted diary card and were included in the analysis. The proportion of patients
who recorded one or more symptomatic hypoglycaemic events during Ramadan
was lower in the sitagliptin group (6.7%) compared with the sulphonylurea group
(13.2%). The risk of symptomatic hypoglycaemia was signiﬁcantly decreased with
sitagliptin relative to sulphonylurea treatment (Mantel–Haenszel relative risk ratio
[95% CI] = 0.51 [0.34, 0.75]; p < 0.001). There were no reported events that
required medical assistance (i.e. visits to physician or emergency room or hospitali-
sations) or were considered severe (i.e. events that caused loss of consciousness,
seizure, coma or physical injury) during Ramadan. Conclusions: In Muslim
patients with type 2 diabetes who observed the fast during Ramadan, switching to
a sitagliptin-based regimen decreased the risk of hypoglycaemia compared with
remaining on a sulphonylurea-based regimen. The incidence of hypoglycaemia was
lower with gliclazide relative to the other sulphonylurea agents and similar to that
observed with sitagliptin.
What’s known
• Muslims are required to abstain from food and
drink from dawn until dusk during the Islamic
holy month of Ramadan.
• Many patients with diabetes fast during Ramadan
despite the potential fasting-related risks and
complications.
• The act of fasting and treatment with certain
antihyperglycaemic agents increase the risk of
hypoglycaemia in patients with type 2 diabetes.
What’s new
• Treatment with sitagliptin, a DPP-4 inhibitor,
reduces the risk of hypoglycaemia compared with
a sulphonylurea in patients with type 2 diabetes
who fast during Ramadan.
• Overall, treatment with sitagliptin or a
sulphonylurea is well tolerated in these patients.
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1132 doi: 10.1111/j.1742-1241.2011.02797.xcations, the American Diabetes Association (ADA)
published recommendations for managing diabetes
during Ramadan (2).
There is no consensus about the most appropriate
oral antihyperglycaemic agent(s) for patients with
type 2 diabetes to use during Ramadan, as there are
limited numbers of clinical trials assessing the efﬁcacy
and safety of these agents during Ramadan. The type
of antihyperglycaemic therapy used may inﬂuence the
risk of hypoglycaemia during a fast, with a higher rate
of hypoglycaemia expected with oral agents that
enhance insulin secretion in a non-glucose-dependent
manner (5). Metformin is recommended because of
the low risk of hypoglycaemia associated with its use,
but the dose schedule may need to be altered to
accommodate changes in meal patterns during Rama-
dan (2). Many patients with type 2 diabetes require
additional antihyperglycaemic treatments to manage
their disease (6). Sulphonylureas are typically recom-
mended in combination with metformin because of
broad clinical experience and lower cost (5). The
ADA recommends caution when using sulphonylureas
during Ramadan (2); sulphonylureas are associated
with an increased risk of hypoglycaemia, but the risk
varies across agents within this class (7,8). In a recent
ﬁve-country observational study, the overall incidence
of symptomatic hypoglycaemia was 20% during Ram-
adan in sulphonylurea-treated Muslims with type 2
diabetes, with a range of 14–26% with the different
sulphonylurea agents (9). In small clinical trials, simi-
lar improvement in glycaemic control and a greater
incidence of hypoglycaemia were observed with glic-
lazide relative to vildagliptin (10,11) and with gliben-
clamide relative to repaglinide (12) during Ramadan.
Given their widespread use and potential for adverse
effects, there is a need for additional clinical studies
evaluating the effects of sulphonylurea compared with
alternative treatment options in patients who fast dur-
ing Ramadan.
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4)
inhibitor, has been shown to be effective and well
tolerated with a low incidence of hypoglycaemia in
clinical trials up to 2 years in duration (13–20).
When added to ongoing metformin monotherapy,
the addition of sitagliptin was shown to reduce the
incidence of symptomatic hypoglycaemia, three to
sixfold, compared with the addition of a sulphonylu-
rea in patients with type 2 diabetes (18–20). Given
the low risk of hypoglycaemia demonstrated in previ-
ous sitagliptin trials in non-fasting patients with type
2 diabetes, it was of interest to evaluate the incidence
of hypoglycaemia with sitagliptin during Ramadan
fasting. The present study was therefore undertaken
to assess the incidence of hypoglycaemia with sitag-
liptin compared with sulphonylurea therapy (with or
without metformin) in Muslim patients with type 2
diabetes who elected to fast during Ramadan.
Methods
Patients and study design
Eligible patients were Muslims with type 2 diabetes
(age ‡ 18 years) who were treated with a stable dose
of sulphonylurea [glimepiride, gliclazide (immediate
or modiﬁed release) or glibenclamide (glyburide)]
with or without metformin for at least the last
3 months prior to enrolment in the study, and had
an HbA1c £ 10% at the screening visit. In addition,
patients expressed their intention to fast during
Ramadan after receiving medical counselling regard-
ing the risks of fasting and provided written
informed consent. The inclusion and exclusion cri-
teria for all patients were subject to veriﬁcation by
a clinical research associate during a routine site
visit. Patients were excluded if they were treated
with antihyperglycaemic agents other than a sulpho-
nylurea with or without metformin, had a history
of severe hypoglycaemia or had contraindications to
treatment with DPP-4 inhibitors. Patients were
recruited from clinical centres in Egypt, Israel,
Jordan, Lebanon, Saudi Arabia and the United Arab
Emirates (UAE). The study was designed in accor-
dance with the principles stated in the Declaration
of Helsinki. The protocol was reviewed and
approved by the appropriate local authorities, as
required, and by the institutional review board or
ethical review committee for each participating clin-
ical centre. The study was conducted from 17 June
2010 to 19 November 2010.
In this open-label study, eligible patients were
randomised in a 1 : 1 ratio to either switch to sitag-
liptin 100 mg qd or to remain on their prestudy sul-
phonylurea (with or without metformin). For
allocation to treatment group, each site was provided
with a randomisation schedule. In countries where
sitagliptin is indicated both as monotherapy and
coadministered with metformin, randomisation was
stratiﬁed by treatment regimen (monotherapy and
coadministration). Following randomisation, patients
and investigators were not blinded to treatment, and
the study proceeded under real-life conditions with-
out any additional protocol-mandated intervention.
Physicians followed their patients as per usual clini-
cal practice and were able to change drug and⁄or
dose if needed to optimally manage their patients
once Ramadan began.
At the screening visit (at least 5 weeks prior to the
start of Ramadan), the following information was
collected: age, gender, history of diabetes and related
complications, weight, height, blood pressure and
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measure HbA1c, fasting blood glucose, total choles-
terol, low density lipoprotein cholesterol, high den-
sity lipoprotein cholesterol, triglycerides and serum
creatinine.
For Ramadan, patients were provided with daily
diary cards to record hypoglycaemic symptoms and
complications, need for assistance due to symptoms
of hypoglycaemia, time from consuming their last
meal and time from taking their last medication dose
to the start of the symptoms of hypoglycaemia and
whether the fast was broken between dawn and dusk.
Eating and drinking after a hypoglycaemic event was
not considered a breaking-the-fast event in this
study. If patients experienced symptoms of hypo-
glycaemia, they were instructed to perform ﬁnger-
stick glucose measurements and to record the
glucose results, as well as, the symptom(s) on their
diary card. A diary card was to be completed by the
patients on a daily basis throughout Ramadan,
regardless of the presence of symptoms. If a patient
experienced multiple symptomatic hypoglycaemic
episodes on the same day, patients were to ﬁll out
diary cards for each episode. In addition, a prepran-
dial blood glucose measurement was to be obtained
prior to the evening meal three times per week on
special colour coded diary cards. At the follow-up
visit at the end of Ramadan (i.e. study end), addi-
tional information was collected including conﬁrma-
tion of observance of the fast during Ramadan and
changes in diabetes medication dose and dose timing
during Ramadan. Safety and tolerability were
assessed by reviewing reported adverse events during
the study. All adverse events were rated by the study
site investigators for intensity (mild, moderate or
severe) and relationship to study drug. Patients were
also contacted by phone 2 weeks after Ramadan to
assess the occurrence of any serious adverse events
since study end.
Outcome variables
The primary end-point was overall incidence of
symptomatic hypoglycaemia recorded during Rama-
dan. Symptomatic events of hypoglycaemia included
any event associated with clinical symptoms such as
faintness, dizziness, headache, confusion, anxiety,
sweating, tremor, palpitations, nausea, pallor and
behavioural changes. The secondary end-point was
the incidence of symptomatic or asymptomatic hypo-
glycaemic events [no reported symptoms, but a
recorded blood glucose £ 70 mg⁄dl (3.9 mmol⁄l)].
Hypoglycaemic events were further categorised as:
symptomatic events conﬁrmed with a corresponding
blood glucose value £ 70 mg⁄dl (3.9 mmol⁄l) or
<5 0m g⁄dl (2.8 mmol⁄l), and severe hypoglycaemia
was deﬁned as events that caused loss of conscious-
ness, seizure, coma or physical injury. In addition,
hypoglycaemic events requiring assistance, either
non-medical (e.g. family member or friend) or medi-
cal (e.g. visits to doctor’s ofﬁce or emergency room
or hospitalisation), were also assessed.
Statistics
Baseline demographics and clinical characteristics
were summarised by treatment group. The All
Patients as Treated (APaT) population was used as
the primary analysis population for this study. The
APaT population consisted of all randomised
patients who received at least one dose of study
treatment and returned at least one completed diary
card during Ramadan. In addition, all patients were
analysed in the treatment groups to which they were
randomised, unless they took incorrect study medica-
tion for the entire treatment period. For the patients
who changed antihyperglycaemic therapy after ran-
domisation, only the hypoglycaemic events that
occurred prior to the change were included in the
analyses. Missing or incomplete diary cards were
considered missing data. A supportive analysis using
the Per-Protocol population was also performed. The
Per-Protocol population was a subset of the APaT
population, and included only those patients who
completed the study and returned at least 70% of
their completed diary cards. The primary and sec-
ondary end-points were assessed using a stratiﬁed
Mantel–Haenszel test for the relative risk, with con-
comitant use of metformin therapy as a stratiﬁcation
factor. The total number of hypoglycaemic events in
each study arm and the types of episodes were also
summarised. A p-value < 0.05 (two-sided) was con-
sidered statistically signiﬁcant. Assuming an inci-
dence of symptomatic hypoglycaemia of 10% in
sulphonylurea-treated patients during Ramadan
[based on the results of Aravind et al. (9)] and that
sitagliptin will reduce the risk by 50%, 434 patients
per arm were required (two-sided a = 0.05, with a
power of 80%). All data analyses were performed
using SAS (Version 9.1.3; Cary, NC).
Results
Investigators from 43 clinical sites in six countries
screened 1243 patients, of whom 1066 were rando-
mised to treatment (n = 529 for sitagliptin and
n = 537 for sulphonylurea). Of the randomised
patients, 1021 (95.8%) were included in the APaT
population (Figure 1). Of the 45 patients excluded
from the APaT population (n = 22 in the sitagliptin
group and n = 23 in sulphonylurea group), 29 did
not return or returned incomplete diary cards, 12
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two were withdrawn post randomisation for not
meeting inclusion criteria (HbA1c > 10% at screening
visit and not on stable dose of sulphonylurea for at
least 3 months prior to screening visit). For the
APaT population, baseline characteristics were gener-
ally similar between treatment groups (Table 1).
Overall, 51% of patients were men, mean age was
55 years and mean HbA1c was 7.5% at baseline
(Table 1). Patients had been on sulphonylurea treat-
ment for a median of 4 years, 92% used sulphonylu-
rea in combination with metformin and 15% self-
reported experiencing a hypoglycaemic event in the
3 months prior to Ramadan (Table 2). For those
who were randomised to remain on their prestudy
sulphonylurea, 35% were treated with glibenclamide,
35% with glimepiride and 30% with gliclazide
(Table 2).
Based on returned diary cards, 93.7% of patients
in the sitagliptin group and 89.7% of patients in the
sulphonylurea group reported that they did not break
the daytime fast (i.e. for reasons other than treating
symptoms of hypoglycaemia) during Ramadan. The
proportion of patients reporting a change in their
diabetes medication dose or timing during Ramadan
was 5.3% in the sitagliptin group and 6.6% in the
sulphonylurea group. During Ramadan, eight
patients in the sitagliptin group had their antihyper-
glycaemic therapy changed (seven to sulphonylurea
and one to insulin). No patients in the sulphonylurea
group changed their antihyperglycaemic therapy.
In the APaT population, the proportion of
patients who recorded one or more symptomatic
hypoglycaemic events during Ramadan was lower in
the sitagliptin group (6.7%) compared with the sul-
phonylurea group (13.2%; Table 3). The risk of
symptomatic hypoglycaemia was signiﬁcantly
decreased with sitagliptin relative to sulphonylurea
treatment (Mantel–Haenszel relative risk ratio [95%
CI] = 0.51 [0.34, 0.75]; p < 0.001). Among the
patients randomised to remain on sulphonylurea
treatment, the proportion of patients reporting
symptomatic hypoglycaemic events was 19.7%
(n⁄n =3 6⁄183) in the glibenclamide, 12.4%
(22⁄178) in the glimepiride and 6.6% (10⁄156) in
the gliclazide subgroups. There was variability across
countries in the proportion of patients reporting
symptomatic hypoglycaemia (Table 3).
Sulphonylurea, n = 537
Excluded, n = 177 
Screen failure        n = 96* 
  HbA1c >10%        n = 78 
  Serum creatinine elevated      n = 11 
  Not on stable-dose sulphonylurea    n = 5 
  Patient not on sulphonylurea      n = 4 
  History of severe hypoglycaemia    n = 1 
Eligible, but not randomised as recruitment target met 
     n = 81
*Two patients with more than one reason for screen 
failure
Discontinued,     n = 16 
Reasons 
￿ Patient withdrew consent  n = 1 
￿ Lost to follow-up   n = 14 
￿ Other     n = 1 
Screened, N = 1243
Sitagliptin, n = 529
Completed study, n = 513 
APaT population
a, n = 507 
PP population
b, n = 356
Completed study, n = 521 
APaT population
a, n = 514 
PP population
b, n = 350
Discontinued,     n = 16 
Reasons 
￿ Patient withdrew consent  n = 1 
￿ Lost to follow-up   n = 15 
Randomised, N = 1066
Figure 1 Patient disposition.
aThe All Patients As Treated (APaT) population consisted of all randomised patients who
received at least one dose of study treatment and returned at least one completed diary card during Ramadan. In addition,
all patients were analysed in the treatment groups to which they were randomised, unless they took incorrect study
medication for the entire treatment period.
bThe Per-Protocol (PP) population was a subset of the APaT population, and
included only those patients who completed the study and returned at least 70% of their diary cards completed
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events were reported during Ramadan by patients in
the APaT population, with 128 events in 34 patients
in the sitagliptin group and 195 events in 68 patients
in the sulphonylurea group. The number of patients
reporting at least three symptomatic hypoglycaemic
Table 1 Baseline characteristics of randomised patients who returned at least one completed daily diary card during
Ramadan
Sitagliptin (n = 507) Sulphonylurea (n = 514)
Country
Egypt, n (%) 62 (12.2) 59 (11.5)
Israel, n (%) 117 (23.1) 122 (23.7)
Jordan, n (%) 45 (8.9) 42 (8.2)
Lebanon, n (%) 81 (16.0) 85 (16.5)
Saudi Arabia, n (%) 192 (37.9) 196 (38.1)
UAE, n (%) 10 (2.0) 10 (1.9)
Patient characteristics
Age at baseline, years (range) 55 ± 11 (24, 94) 55 ± 10 (23, 87)
Gender male, n (%) 269 (53) 255 (50)
BMI, kg⁄m
2 30.5 ± 5.7 30.5 ± 5.6
HbA1c, % 7.5 ± 1.3 7.6 ± 1.2
Fasting blood glucose, mg⁄dl 150 ± 52 153 ± 50
Duration of diabetes, years* 5.0 6.0
Systolic blood pressure, mmHg 130 ± 13 129 ± 14
Diastolic blood pressure, mmHg 78 ± 8 77 ± 8
Total cholesterol, mg⁄dl 179 ± 42 185 ± 43
LDL-cholesterol, mg⁄dl 106 ± 35 110 ± 36
HDL-cholesterol, mg⁄dl 42 ± 11 44 ± 18
Triglycerides, mg⁄dl* 148 150
Serum creatinine, mg⁄dl 0.7 ± 0.4 0.7 ± 0.4
Diabetes- and cardiovascular-related complications and comorbidities
Neuropathy, n (%) 109 (22) 109 (21)
Retinopathy, n (%) 50 (10) 45 (9)
Nephropathy, n (%) 41 (8) 32 (6)
Coronary artery disease, n (%) 45 (9) 33 (7)
Peripheral arterial disease, n (%) 7 (1) 5 (1)
Cerebrovascular diseases, n (%) 8 (2) 3 (1)
Hypertension 214 (42) 221 (43)
Dyslipidaemia 316 (62) 317 (62)
*Median. Data are expressed as frequency, n (%) or mean ± SD unless otherwise indicated. To convert fasting blood glucose from
mg⁄dl to mmol⁄l multiply by 0.0555. To convert cholesterol values from mg⁄dl to mmol⁄l multiply by 0.0259. To convert triglycerides
from mg⁄dl to mmol⁄l multiply by 0.0113. To convert serum creatinine from mg⁄dl to lmol⁄l multiply by 88.4. UAE, United Arab
Emirates; BMI, body mass index; MET, metformin.
Table 2 Sulphonylurea (SU) use prior to randomisation to treatment group
Sitagliptin (n = 507) Sulphonylurea (n = 514)
Glibenclamide 158 (31) 181 (35)
Glimepiride 189 (37) 178 (35)
Gliclazide 159 (32) 152 (30)
Monotherapy, n (%) 41 (8) 41 (8)
Dual: SU + MET, n (%) 465 (92) 471 (92)
Duration of SU therapy*, years 4.0 4.0
Experienced hypoglycaemia in 3 months prior to Ramadan 81 (16) 76 (15)
*Median. Data are expressed as frequency, n (%) unless otherwise indicated.
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group and 52 in the sulphonylurea group. The most
commonly reported symptoms were headache, sweat-
ing, dizziness, hunger and tremor. The median time
from the last meal to the onset of hypoglycaemic
event was approximately 6 h.
Of the 1066 randomised patients, 706 (66.2%)
patients met the Per-Protocol criteria (i.e. rando-
mised patients who completed the study and
returned at least 70% of their diary cards com-
pleted), with 356 patients in the sitagliptin group
and 350 in the sulphonylurea group. In the Per-Pro-
tocol population, the proportion of patients who
recorded one or more symptomatic hypoglycaemic
events during Ramadan was 4.8% (n = 17) in the
sitagliptin group and 14.3% (n = 50) in the sulpho-
nylurea group (Mantel–Haenszel relative risk ratio
[95% CI] = 0.33 [0.20, 0.57]; p < 0.001).
The proportion of patients with either symptom-
atic or asymptomatic hypoglycaemic events was 8.5%
in the sitagliptin group and 17.9% in the sulpho-
nylurea group (Table 4). The risk of symptomatic or
asymptomatic hypoglycaemia was signiﬁcantly
decreased with sitagliptin relative to sulphonylurea
treatment (Mantel–Haenszel relative risk ratio [95%
CI] = 0.50 [0.36, 0.69]; p < 0.001). The proportion
of patients with symptomatic hypoglycaemia con-
ﬁrmed with a corresponding blood glucose value
£ 70 mg⁄dl (3.9 mmol⁄l) was 1.6% (n = 8) in the
sitagliptin group and 4.3% (n = 22) in the sulpho-
nylurea group. Two patients (0.4%) in the sitagliptin
group and nine (1.8%) in the sulphonylurea group
had a symptomatic hypoglycaemic event with a cor-
responding blood glucose value < 50 mg⁄dl
(2.8 mmol⁄l). The incidence of hypoglycaemic events
requiring non-medical assistance was low, with 0.2%
of patients in the sitagliptin group and 0.8% in the
sulphonylurea group. There were no reported events
that required medical assistance (i.e. visits to physi-
cian or emergency room or hospitalisations) or were
considered severe (i.e. events that caused loss of con-
sciousness, seizure, coma or physical injury) during
Ramadan (Table 4).
In addition to events of hypoglycaemia, 19 other
adverse events were recorded during Ramadan. In the
sitagliptin group, three patients reported a total of
three adverse events: constipation, hyperglycaemia and
vomiting. In the sulphonylurea group, nine patients
reported a total of 16 adverse events: unstable angina,
asthenia (n = 2 patients), cough, ischaemic stroke,
acute pancreatitis, somnolence (n = 9) and urinary
tract infection. No deaths were reported during Rama-
dan. Three of the aforementioned adverse events (is-
chaemic stroke, acute pancreatitis and urinary tract
infection) in the sulphonylurea treatment group
resulted in hospitalisation and thus were considered
serious adverse events. No serious adverse events were
reported for the sitagliptin group.
Discussion
This large, prospective, randomised, multicentre
study evaluated the incidence of symptomatic hypo-
glycaemia during Ramadan in Muslim patients with
type 2 diabetes who remained on their prestudy sul-
phonylurea or switched to sitagliptin (with or with-
out metformin). In this study, overall 92% reported
that they did not break the daytime fast during
Table 3 Proportion of patients reporting symptomatic
hypoglycaemia during Ramadan overall and by country
n⁄N (%)* Sitagliptin Sulphonylurea
Overall 34⁄507 (6.7) 68⁄514 (13.2)
Egypt 0⁄62 (0) 11⁄59 (18.6)
Israel 20⁄117 (17.1) 32⁄122 (26.2)
Jordan 3⁄45 (6.7) 3⁄42 (7.1)
Lebanon 8⁄81 (9.9) 19⁄85 (22.4)
Saudi Arabia 1⁄192 (0.5) 1⁄196 (0.5)
UAE 2⁄10 (20.0) 2⁄10 (20.0)
*No. of patients experiencing event⁄no. of patients overall or
in each country by treatment (%).
Table 4 Proportion of patients reporting hypoglycaemia during Ramadan by type* of event
Sitagliptin (n = 507)
no. (%) of patients
experiencing event
Sulphonylurea (n = 514)
no. (%) of patients
experiencing event
Symptomatic or asymptomatic hypoglycaemic events 43 (8.5) 92 (17.9)
Severe hypoglycaemic events 0 0
Hypoglycaemic events requiring non-medical assistance 1 (0.2) 4 (0.8)
Hypoglycaemic events requiring medical assistance 0 0
*Types of hypoglycaemic event deﬁned in Methods.
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emia in the APaT population was 6.7% with sitaglip-
tin and 13.2% with sulphonylurea. Thus, the risk of
symptomatic hypoglycaemia was decreased by nearly
50% with sitagliptin relative to sulphonylurea treat-
ment. Moreover, in the Per-Protocol analysis, the
risk of symptomatic hypoglycaemia was decreased by
67% with sitagliptin. These results were further sup-
ported by the lower incidence of symptomatic hypo-
glycaemia conﬁrmed with a corresponding blood
glucose value £ 70 mg⁄dl (3.9 mmol⁄l) with sitaglip-
tin. There were no reports of severe hypoglycaemia,
as deﬁned in this study, and no reports of patients
requiring hospitalisation or visits to their physicians
due to a hypoglycaemic event. This is in contrast to
previous reports of 0.5–2% of patients requiring hos-
pitalisation for hypoglycaemia during Ramadan
(4,9). The lower risk of hypoglycaemia with sitaglip-
tin relative to sulphonylureas overall is consistent
with the glucose-dependent actions of DPP-4 inhibi-
tors relative to the non-glucose-dependent mecha-
nism of action of potassium channel-based insulin
secretagogues, such as sulphonylureas (5,21).
The difference in hypoglycaemia between sitaglip-
tin and sulphonylurea was driven by the higher inci-
dence of hypoglycaemia observed in the
glibenclamide- and glimepiride-treated patients. The
present ﬁndings are consistent with those from clini-
cal trials not conducted during Ramadan that found
a signiﬁcantly lower incidence of hypoglycaemia with
sitagliptin compared with glipizide or glimepiride
(18–20). The incidence of hypoglycaemia was similar
between sitagliptin and gliclazide in the present
study. The lower incidence of hypoglycaemia
observed in the gliclazide group relative to other sul-
phonylureas is consistent with results observed in
other studies conducted during (9) and not during
Ramadan (22). Thus, selection of sulphonylurea may
impact the risk of hypoglycaemia during Ramadan.
Few clinical trials have compared the efﬁcacy and
safety of antihyperglycaemic agents in fasting patients
with type 2 diabetes during Ramadan. In small
observational studies (£ 72 patients⁄study) from the
UK, the incidence of hypoglycaemia was compared
between Muslim patients with type 2 diabetes on
vildagliptin, a DPP-4 inhibitor or gliclazide during
Ramadan (10,11). In these trials, the proportion of
patients with at least one hypoglycaemic episode was
signiﬁcantly lower with vildagliptin (0–8%) than
with gliclazide (42–62%). Differences in study design
(e.g. sample size, observational vs. randomised trial,
deﬁnition of hypoglycaemia) may account for the
higher incidence of hypoglycaemia reported with
gliclazide relative to the incidence observed with sul-
phonylurea in the present study. In addition, in one
of these prior studies (10), gliclazide was initiated at
the beginning of Ramadan. It is possible that the
higher incidence of hypoglycaemia was related to this
fact, as hypoglycaemia rates may be higher during
initiation of sulphonylurea therapy. Furthermore, the
patients in that study were not randomly assigned to
treatment with gliclazide, raising the possibility that
a bias was introduced into the treatment assign-
ments. Clearly, however, treatment with a DPP-4
inhibitor (sitagliptin or vildagliptin) reduces the inci-
dence of hypoglycaemia relative to treatment with a
sulphonylurea agent during Ramadan.
In another study using a treatment switch design,
235 Muslim patients with type 2 diabetes previously
treated with a sulphonylurea were randomised to
remain on a sulphonylurea (glibenclamide) or switch
to repaglinide 6 weeks before Ramadan (12). Both
treatments were titrated to optimal dose in the
6 weeks before Ramadan. During Ramadan, the inci-
dence of symptomatic hypoglycaemia was 7% in the
repaglinide group and 8% in the glibenclamide group.
The incidence of conﬁrmed symptomatic hypoglyca-
emia (events with a corresponding blood glucose value
of < 2.8 mmol⁄l) was lower in the repaglinide group
compared with the glibenclamide group (2% vs. 4%).
In other smaller trials with various study designs, no
differences were observed in the incidence of hypogly-
caemic events between a sulphonylurea and active
comparators (repaglinide, insulin glargine) (23,24).
The incidence of symptomatic hypoglycaemia var-
ied by country in the present study. In particular,
the proportion of patients reporting hypoglycaemia
was unexpectedly low in patients from Saudi Arabia
despite comprising nearly 40% of the randomised
population. While there may be potential under-
reporting of hypoglycaemia by patients from Saudi
Arabia, review of the diary cards completed by all
patients did not show any apparent study design-
related factors that would affect the validity of the
present ﬁndings. A similar pattern of country-speciﬁc
variability was recently described in sulphonylurea-
treated patients (9). In Aravind et al. (9), the pro-
portion of patients reporting hypoglycaemia was low-
est in patients from Saudi Arabia (10%) relative to
the overall cohort (20%). Aravind et al. speculated
that the differences across countries may be related
to differences in patient characteristics, variations in
physicians’ practices to modify the doses of antihy-
perglycaemic medications or the timing of adminis-
tration to coincide with the fasting period of
Ramadan or variations in dietary and lifestyle habits
during Ramadan. Reasons for differences across
countries were not assessed in the present study.
The following strengths and limitations of this
study should be acknowledged. The study evaluated
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design with over 1000 Muslim patients from six dif-
ferent countries. Subjects were required to record hy-
poglycaemic symptoms (or no symptoms) daily
during Ramadan rather than recall hypoglycaemic
events at a ﬁnal study visit. The primary end-point,
symptomatic hypoglycaemic events, did not require a
conﬁrmatory blood glucose measurement, which
may have overestimated hypoglycaemic events. How-
ever, the ﬁndings of symptomatic hypoglycaemia
with a corresponding blood glucose £ 70 mg⁄dl
[3.9 mmol⁄l] support the primary ﬁndings of a
higher incidence of symptomatic hypoglycaemia with
sulphonylurea compared with sitagliptin. Although
15% of patients self-reported experiencing a hypogly-
caemic event on their sulphonylurea-based regimen
in the 3 months prior to Ramadan, the incidence of
hypoglycaemia was not formally assessed with sitag-
liptin or sulphonylurea before or after Ramadan. The
effect of treatment on glycaemic control and body
weight was not assessed during Ramadan in the pres-
ent study. In previous clinical trials not conducted
during Ramadan, the glucose-lowering efﬁcacy of
sitagliptin and a sulphonylurea (glipizide or glimepi-
ride) was similar, whereas treatment with sitagliptin
led to weight loss relative to weight gain with the
sulphonylurea (18–20).
Conclusions
In Muslim patients with type 2 diabetes who observed
the fast during Ramadan, switching treatment to a si-
tagliptin-based regimen decreased the risk of hypo-
glycaemia compared with remaining on a
sulphonylurea-based regimen. In this study, the inci-
dence of hypoglycaemia was lower with gliclazide rela-
tive to the other sulphonylurea agents and similar to
that observed with sitagliptin. Both treatment regi-
mens were generally well tolerated during the month
of Ramadan.
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